Shots:

• The P-III KEYNOTE-355 (part 1 & 2) study involves assessing of Keytruda (200mg- IV- on day 1 of each 21-day cycle) + CT vs PBO + CT in 30 & 847 patients with LA inoperable or mTNBC prior not treated with CT in the metastatic setting
• The P-III KEYNOTE-355 study resulted in meeting one of its dual 1EPs i.e- improvement in PFS- the safety profile is consistent with the previous studies with no new safety signals. Following the recommendation of DMC- the study will continue its other 1EPs of OS
• Keytruda is an anti-PD-1 therapy- act by blocking the interaction between PD-1 and its ligands- PD-L1 and PD-L2 thus activating T lymphocytes affecting both tumor and healthy cells

Click here to­ read full press release/ article 

Ref: Merck | Image: Merck